國立高雄大學圖資館 |

Language: English

Back

Targeted therapy of colorectal cance...

Jordan, Peter.

Targeted therapy of colorectal cancer subtypes

Record Type:	Electronic resources : Monograph/item
Title/Author:	Targeted therapy of colorectal cancer subtypesedited by Peter Jordan.
other author:	Jordan, Peter.
Published:	Cham :Springer International Publishing :2018.
Description:	viii, 150 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Colon (Anatomy)Cancer
Online resource:	https://doi.org/10.1007/978-3-030-02771-1
ISBN:	9783030027711$q(electronic bk.)

Targeted therapy of colorectal cancer subtypes
Targeted therapy of colorectal cancer subtypes[electronic resource] /edited by Peter Jordan. - Cham :Springer International Publishing :2018. - viii, 150 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.11100065-2598 ;. - Advances in experimental medicine and biology ;946..

Preface -- Colorectal Cancer Subtypes- the current portrait -- Targeting colon cancers with mutated BRAF and microsatellite instability -- Targeting KRAS mutant CMS3 subtype by metabolic inhibitors -- Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer -- Targeting PTEN in colorectal cancers -- Wnt signalling-targeted therapy in the CMS2 tumour subtype: a new paradigm in CRC treatment?- Impact of the microenvironment on tumour budding in colorectal cancer -- Anti-EGFR Therapy to treat metastatic colorectal cancer: not for all -- miRNAs as modulators of EGFR therapy in colorectal cancer -- Index.

In this book, a group of researchers shares their expertise on the identification and characterization of genetic colorectal cancer subtypes. They describe solid pathobiological knowledge on the distinct sporadic tumour subtypes, including the mutations found in oncogenes and tumour suppressor genes, the types of genomic instability encountered, and the cellular signalling pathways activated. The book content indicates opportunities for the development of further pathway-specific therapeutic drugs or drug combinations, allowing to cope with the appearance of resistant tumours. The nine chapters of this book cover the main aspects underlying colorectal cancer development but also of its therapeutic options, which have been undergoing substantial changes by moving from the use of general cytotoxic agents that affect rapidly growing cells to more tumour-specific drugs. In the first case, all dividing cells in the patient's body are affected and this causes severe and debilitating side effects. In the second case, the increasing knowledge about the molecular genetics of tumours has led to a new generation of drugs, which specifically interfere with the cell survival pathways that are activated in a given tumour. This allowed to identify groups of patients for targeted therapy that is much better tolerated. The book is thus an interesting update for health professionals on the current knowledge on heterogeneity in colorectal cancer. In addition, it should inspire the drug-developing scientific community by highlighting potential therapeutic Achilles heels of distinct subtypes of colorectal cancer.

ISBN: 9783030027711$q(electronic bk.)

Standard No.: 10.1007/978-3-030-02771-1doiSubjects--Topical Terms:

825643
Colon (Anatomy)
--Cancer

LC Class. No.: RC280.C6 / T374 2018

Dewey Class. No.: 616.994347061

Targeted therapy of colorectal cancer subtypes
LDR:03311nmm a2200337 a 4500 001 546661
003 DE-He213
005 20190508141201.0
006 m d
007 cr nn 008maaau
008 190627s2018 gw s 0 eng d
020 $a 9783030027711$q(electronic bk.)
020 $a 9783030027704$q(paper)
024 7 $a 10.1007/978-3-030-02771-1 $2 doi
035 $a 978-3-030-02771-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.C6 $b T374 2018
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994347061 $2 23
090 $a RC280.C6 $b T185 2018
245 0 0 $a Targeted therapy of colorectal cancer subtypes $h [electronic resource] / $c edited by Peter Jordan.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a viii, 150 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.1110
505 0 $a Preface -- Colorectal Cancer Subtypes- the current portrait -- Targeting colon cancers with mutated BRAF and microsatellite instability -- Targeting KRAS mutant CMS3 subtype by metabolic inhibitors -- Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer -- Targeting PTEN in colorectal cancers -- Wnt signalling-targeted therapy in the CMS2 tumour subtype: a new paradigm in CRC treatment?- Impact of the microenvironment on tumour budding in colorectal cancer -- Anti-EGFR Therapy to treat metastatic colorectal cancer: not for all -- miRNAs as modulators of EGFR therapy in colorectal cancer -- Index.
520 $a In this book, a group of researchers shares their expertise on the identification and characterization of genetic colorectal cancer subtypes. They describe solid pathobiological knowledge on the distinct sporadic tumour subtypes, including the mutations found in oncogenes and tumour suppressor genes, the types of genomic instability encountered, and the cellular signalling pathways activated. The book content indicates opportunities for the development of further pathway-specific therapeutic drugs or drug combinations, allowing to cope with the appearance of resistant tumours. The nine chapters of this book cover the main aspects underlying colorectal cancer development but also of its therapeutic options, which have been undergoing substantial changes by moving from the use of general cytotoxic agents that affect rapidly growing cells to more tumour-specific drugs. In the first case, all dividing cells in the patient's body are affected and this causes severe and debilitating side effects. In the second case, the increasing knowledge about the molecular genetics of tumours has led to a new generation of drugs, which specifically interfere with the cell survival pathways that are activated in a given tumour. This allowed to identify groups of patients for targeted therapy that is much better tolerated. The book is thus an interesting update for health professionals on the current knowledge on heterogeneity in colorectal cancer. In addition, it should inspire the drug-developing scientific community by highlighting potential therapeutic Achilles heels of distinct subtypes of colorectal cancer.
650 0 $a Colon (Anatomy) $x Cancer $x Chemotherapy. $3 825643
650 0 $a Rectum $x Cancer $x Chemotherapy. $3 825644
650 0 $a Drug targeting. $3 194481
650 1 4 $a Cancer Research. $3 273660
650 2 4 $a Human Genetics. $3 273658
650 2 4 $a Molecular Medicine. $3 273932
650 2 4 $a Biomedical Engineering/Biotechnology. $3 730838
650 2 4 $a Immunology. $3 189152
700 1 $a Jordan, Peter. $3 825642
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 557559
856 4 0 $u https://doi.org/10.1007/978-3-030-02771-1
950 $a Biomedical and Life Sciences (Springer-11642)